Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

By P. Elliott, J. Poloniecki, S. Dickie, Sanjay Sharma, L. Monserrat, A. Varnava, N. Mahon, W. McKenna. Journal of the American College of Cardiology, 2000

949 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/63b7df19eb65f351ac0fb1e9e8da730e13053efe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Hypertrophic cardiomyopathy: a systematic review. (2002, background): “Objectives To clarify and summarize the relevant clinical issues and to profile rapidly evolving concepts regarding HCM. Data Sources Systematic analysis of the relevant HCM literature, accessed through MEDLINE (1966-2000), bibliographies, and interactions with investigators.”
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. (2008, background): “Therefore, in selected patients, it is possible that some weight can be given to areas of DE as an arbitrator in reaching recommendations for prophylactic ICDs when ambiguity remains concerning individual patient risk of sudden death after assessing the conventional risk factors (2,3, 31 ,34).”
Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations (2012, neutral): “59,60 Moreover, prognostic implications are even worse when abnormal haemodynamic responses are coupled to a low peak V O 2 .”
Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014, neutral): “These approaches still require broad-based validation (20,32).”
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, background): “Others have suggested that patients with extreme septal hypertrophy also have other risk factors, and the independent value of extreme septal hypertrophy is less clear (98,679).”
Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001, background): “SCD prevention with the ICD is most strongly recommended for patients surviving prior cardiac arrest and for primary prevention in patients with two or more risk factors (identified during non-invasive risk stratification) in whom annual SCD rates are 3–6% or more([273,274,285,287]).”